Low-toxicity vitrification agents
Cryoprotectant cocktails that stop ice formation throughout a large perfused tissue at concentrations the cells survive.
State of the art
VS55 and M22 vitrification cocktails combined with iron-oxide nanoparticles enabled recovery of vitrified rat kidneys (2023); a non-metabolizable sugar plus ice-nucleating Snomax allowed partial-freezing storage of human livers for days (2023).
- Cryoprotectant concentrations that prevent ice (over 50 percent w/v) are chemically toxic over the hours needed to load a large organ
- Perfusion is uneven - poorly vascularized regions receive too little agent and nucleate ice
- Devitrification during rewarming happens faster than agents can suppress in large volumes
Who’s working on it
- John BischofResearcherUniversity of Minnesota
Directs NSF ATP-Bio; his group's iron-oxide nanowarming plus M22-class cocktails enabled recovery of vitrified rat kidneys (2023) and, with MGH, the first transplant of a cryopreserved large-mammal kidney
NSF Engineering Research Center (grant EEC-1941543) co-led by the University of Minnesota and Mass General Brigham; its Year 4 report cites $30M of leveraged non-ERC funding and it was the only ERC highlighted in NSF's FY2027 budget request
- Until Labs ↗Startup
Building reversible organ cryopreservation end to end; reported expanding its cryoprotectant discovery engine from dozens to over 250,000 candidate molecules (2026) alongside organ-scale magnetic rewarming
- Shannon TessierResearcherMassachusetts General Hospital
Developed partial-freezing and supercooling protocols, including non-metabolisable sugar plus ice-nucleation storage that kept human livers viable for days (2023)
- 21st Century MedicineCompany
Developed the VS55 and M22 vitrification cocktails that remain the field's reference formulations, and the first vitrified-and-rewarmed rabbit kidney work
- NSF EARTH Engineering Research CenterProgram
NSF center (grant ECC-2330175) at the University of Kansas working with ATP-Bio on liquid refrigerants that cool organs fast enough to cut required cryoprotectant concentrations
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | High-throughput screening of ice-binding proteins and sugar mixtures ranked by glass-forming ability per unit toxicity | $$ $10M – $100M |
| engineering | Instrumented perfusion rigs that map agent concentration spatially in organ-scale tissue during loading | $$ $10M – $100M |